Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients
Lehoczky, O.; Bagaméri, A.; Udvary, J.; Pulay, T.
Journal of Obstetrics and Gynaecology the Journal of the Institute of Obstetrics and Gynaecology 22(3): 312-313
2002
ISSN/ISBN: 0144-3615 PMID: 12521509 DOI: 10.1080/01443610220130661Document Number: 250119
Document emailed within 0-6 h
Related Documents
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15Bookman, M.A.; Kloth, D.D.; Kover, P.E.; Smolinski, S.; Ozols, R.F. 1997: Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions Seminars in Oncology 24(6 Suppl 19: S19
Rezáč, A.; Jílek, P.; Rezáčová, V.; Skapinec, P.; Sedláková, I.; Tošner, J.; Spaček, J. 2013: Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences Ceska Gynekologie 78(6): 514-521
Henry, A.; Charpiat, B.; Perol, M.; Vial, T.; de Saint Hilaire, P.Jousselin.; Descotes, J. 2006: Paclitaxel hypersensitivity reactions: assessment of the utility of a test-dose program Cancer Journal 12(3): 237-245
Ten Bokkel Huinink, W.; Veenhof, C.; Helmerhorst, T.; Bierhorst, F.; Dalesio, O.; Winograd, B.; Depauw, L.; Pinedo, H.M. 1995: Paclitaxel plus carboplatin in the treatment of ovarian cancer Seminars in Oncology 22(3 Suppl 6: 97-100
Ozols, R.F. 1999: Paclitaxel plus carboplatin in the treatment of ovarian cancer Seminars in Oncology 26(1 Suppl 2: 84-89
Markman, M. 1995: Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer Seminars in Oncology 22(3 Suppl 6: 88-89
Ozols, R.F. 2000: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer Seminars in Oncology 27(3 Suppl 7: 3-7
Ezcurdia, L.; Jovtis, S.L.; Mickiewicz, E.; Temperley, G.; Rondinón, M.; Blajman, C.; Cóppola, F.S.; Lewi, D.; Cazap, E.; Breier, S.; Fasce, H.; Fein, L.; Polera, J.; Triguboff, E.; Uranga, G.; Pasccón, G.; Luchina, A.M.; Martínez, C.A.; Politi, P.M.; Rubio, G.; Alvarez, A.M. 1997: Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group Seminars in Oncology 24(5 Suppl. 15): S15
Mayerhofer, K.; Bodner-Adler, B.; Bodner, K.; Saletu, B.; Schindl, M.; Kaider, A.; Hefler, L.; Leodolter, S.; Kainz, C. 2000: A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer Anticancer Research 20(5c): 4051-4055
Gadducci, A.; Cianci, C.; Cosio, S.; Carnino, F.; Fanucchi, A.; Buttitta, F.; Conte, P.F.; Genazzani, A.R. 2000: P53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen Anticancer Research 20(6c): 4793-4799
Watari, H.; Hosaka, M.; Mitamura, T.; Moriwaki, M.; Ohba, Y.; Todo, Y.; Takeda, M.; Ebina, Y.; Sakuragi, N. 2008: Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience European Journal of Gynaecological Oncology 29(6): 573-577
Komatsubara, K.; Miyoshi, K.; Kogure, Y.; Matsuhisa, T.; Eguchi, H. 2010: Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(1): 107-110
Takano, M.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Ohwada, M.; Yamamoto, T.; Yamamoto, K.; Inoue, H.; Shimizu, K. 2002: Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer Anticancer Research 22(3): 1833-1838
Scarfone, G.; Villa, A.; Parazzini, F.; Sciatta, C.; Polverino, G.; Bolis, G. 1999: A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy Tumori 85(4): 217-219
Skarlos, D.V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G.P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. 1997: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study Seminars in Oncology 24(5 Suppl 15: S15
Wojciechowska-Lacka, A.; Markowska, J.; Skasko, E.; Kruczek, A.; Steffen, J. 2003: Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report) European Journal of Gynaecological Oncology 24(1): 21-24
Shuvaeva, N.I.; Emel'ianova, L.S. 1974: Toxic reactions during treatment of the ovarian cancer with ThioTEPA Akusherstvo i Ginekologiia 10: 18-20
Dukes, C.S.; Sugarman, J.; Cegielski, J.P.; Lallinger, G.J.; Mwakyusa, D.H. 1992: Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania Tropical and Geographical Medicine 44(4): 308-311
Suwannarurk, K.; Thaweekul, Y.; Mairaing, K.; Poomtavorn, Y.; Tangtiang, K.; Piyawang, W.; Bhamarapravatana, K. 2015: Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report Journal of the Medical Association of Thailand 98 Suppl. 3: S121-S125